Medical/Pharmaceuticals

Medit Launches Medit i900 classic, a New Addition to Medit i900 Family Line Up

SEOUL, South Korea and NEWPORT BEACH, Calif., March 25, 2025 /PRNewswire/ -- Medit (www.medit.com ), a global leader in digital dentistry, is unveiling its latest scanner, the Mediti900 classic, as part of the Mediti900 Family. Launched on March 25, the Medit i900 classic p...

2025-03-25 15:00 3240

WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024

* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 * Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentag...

2025-03-24 22:45 3186

Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics

Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically...

2025-03-24 22:30 1780

Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval

NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...

2025-03-24 21:00 1572

Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...

2025-03-24 20:30 1858

SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS

BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...

2025-03-24 20:00 3227

Fangzhou Inc. Reports Strong Growth in 2024 Annual Results: 11.2% Revenue Growth and 139% Year-on-Year Increase in Adjusted Net Profit Driven by AI-Powered Innovation

HONG KONG, March 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue ofRMB 2.7 billion, representing an 11.2% year-over-year inc...

2025-03-24 11:00 2936

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...

2025-03-24 08:15 2160

Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019

-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...

2025-03-24 07:56 2081

Aphranel® MagiCCrystal CaHA Filler from Shanghai MOYOM Biotec, Obtains NMPA Class III Medical Device Certificate in China

——The World's First Precisely Regulated Injectable CaHA Filler, Accelerating Compliance in the Medical Aesthetics Industry inChina. SHANGHAI, March 21, 2025 /PRNewswire/ -- Shanghai Moyom Biotechnology's high-profile brand,Aphranel® MagiCCrystal CaHA Filler, has officially obtained Class III Med...

2025-03-21 21:00 3882

Syneron Bio Announces Strategic Collaboration with AstraZeneca

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic ...

2025-03-21 20:02 2405

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global ...

2025-03-21 19:21 2447

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific ...

2025-03-21 11:14 2137

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...

2025-03-21 08:30 1910

Wounds hard to heal? Troubled by dressing changes? Dimora, Amazon's 3-year top brand, shows you the way.

NEW YORK, March 20, 2025 /PRNewswire/ -- Dimora Medical , a continuous innovator in high-end medical care supplies, has secured the number one spot in Amazon's Wound Dressings category for the third year. With over 33 million wound dressings sold since its 2019 debut,...

2025-03-21 01:08 1929

Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025

* Company Joins NVIDIA Healthcare & Life Sciences (HCLS) Ecosystem to Advance Global Diagnostic Accessibility and Seeks Partnerships with Global Healthcare Opportunities YONGIN, South Korea, March 20, 2025 /PRNewswire/ -- Noul Co., Ltd.  a Korea-based medical AI company, announced that it presen...

2025-03-21 00:00 3033

Seegene Unveils HPV Genotyping Solution at EUROGIN 2025

-    Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held inPortugal from March 16-19 -    Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals SEOUL, South K...

2025-03-20 21:00 2035

LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient

SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announced on the2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing th...

2025-03-20 21:00 2097

TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development

* Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) inChina SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage biopharmace...

2025-03-20 20:00 1856

Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer

* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL * The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmac...

2025-03-20 18:00 1796
1 ... 40414243444546 ... 248

Week's Top Stories